Regeneron Pharmaceuticals Profit Margin

Regeneron Pharmaceuticals (REGN) currently reports a profit margin of 27.86% as of June 2026. That compares with 31.37% in the prior-year period — down 11.2% year over year. That is above the Healthcare sector average of 21.34%. Use the charts on this page to explore Regeneron Pharmaceuticals's profit margin history and peer comparisons.

Regeneron Pharmaceuticals's profit margin decreased from 31.37% to 27.86% — a 11.2% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Regeneron Pharmaceuticals's profit margin of 27.86% is higher than the Healthcare sector average of 21.34%. That is roughly 30.6% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Regeneron Pharmaceuticals's current 27.86% should be judged against Healthcare norms (sector average: 21.34%) and against REGN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 27.86%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Regeneron Pharmaceuticals, and consider following REGN for alerts when major investors trade the stock.